News Image

Is VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) suited for growth investing?

By Mill Chart

Last update: Apr 17, 2024

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) is suited for growth investing. Investors should of course do their own research, but we spotted VOYAGER THERAPEUTICS INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

Key Considerations for Growth Investors.

  • VOYAGER THERAPEUTICS INC has achieved an impressive Return on Equity (ROE) of 55.98%, showcasing its ability to generate favorable returns for shareholders.
  • VOYAGER THERAPEUTICS INC has consistently exceeded EPS estimates in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
  • With impressive 1-year revenue growth of 510.0%, VOYAGER THERAPEUTICS INC showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
  • VOYAGER THERAPEUTICS INC has experienced 6.0K% q2q revenue growth, indicating a significant sales increase.
  • With positive growth in its operating margin over the past year, VOYAGER THERAPEUTICS INC showcases its ability to improve profitability through effective cost control and operational efficiency. This growth underscores the company's commitment to enhancing its financial performance.
  • The free cash flow (FCF) of VOYAGER THERAPEUTICS INC has seen steady growth over the past year, indicating enhanced cash flow generation and financial health. This trend underscores the company's effective capital management and its ability to generate sustainable cash flows.
  • The earnings per share (EPS) of VOYAGER THERAPEUTICS INC have shown positive growth on a quarter-to-quarter (Q2Q) basis, with a 305.0% increase. This reflects the company's ability to improve its profitability over time.
  • Over the past 3 months, analysts have adjusted their EPS Estimate for VOYAGER THERAPEUTICS INC with a 34.33% change. This highlights the evolving outlook on the company's EPS potential.
  • The quarterly earnings of VOYAGER THERAPEUTICS INC have shown a 305.0% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
  • The earnings per share (EPS) growth of VOYAGER THERAPEUTICS INC are accelerating: the current Q2Q growth of 305.0% is above the previous year Q2Q growth of -507.0%. Earnings momentum and acceleration are key for high growth systems.

Fundamental analysis of NASDAQ:VYGR

ChartMill utilizes a proprietary algorithm to assign a Fundamental Rating to every stock. This rating, ranging from 0 to 10, is computed daily by analyzing a variety of fundamental indicators and properties.

VYGR gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. VYGR has an excellent financial health rating, but there are some minor concerns on its profitability. VYGR has a correct valuation and a medium growth rate.

Check the latest full fundamental report of VYGR for a complete fundamental analysis.

Our Lois Navellier screen will find you more ideas suited for growth investing.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

VOYAGER THERAPEUTICS INC

NASDAQ:VYGR (5/17/2024, 7:00:02 PM)

After market: 8.43 0 (0%)

8.43

-0.2 (-2.32%)

VYGR News

News Image3 days ago - Voyager Therapeutics, Inc.Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...

News Image5 days ago - InvestorPlaceVYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024

VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image5 days ago - BusinessInsiderVYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Voyager Therapeutics (NASDAQ:VYGR) just reported results for the first quarter ...

News Image5 days ago - Voyager Therapeutics, Inc.Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single...

News Image11 days ago - Voyager Therapeutics, Inc.Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and...

News Image13 days ago - Voyager Therapeutics, Inc.Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...

News Image24 days ago - Market News VideoCommit To Purchase Voyager Therapeutics At $5, Earn 12.4% Annualized Using Options
News Imagea month ago - Voyager Therapeutics, Inc.Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against...

News Imagea month ago - Voyager Therapeutics, Inc.Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

News Imagea month ago - Market News VideoVoyager Therapeutics Breaks Below 200-Day Moving Average - Notable for VYGR
News Imagea month ago - Market News VideoInvestors Snag VYGR Even Cheaper Than Its Secondary Stock Offering
News Image2 months ago - InvestorPlaceThe Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.

VYGR Links
Follow us for more